Drugs / ASN-3186
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06787950 | Feb 2025 → Mar 2029 expected | cancer | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN-3186 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06787950 ↗ |
| Route | Oral | “ASN-3186 will be administered orally.” NCT06787950 ↗ |